Amgen Inc. (NASDAQ:AMGN) is reporting second quarter financial results on Tuesday 28th July 2020, after market close.
According to analysts surveyed by Thomson Reuters, AMGN is expected to report 2Q20 income of $ 3.84 per share from revenue of $ 6182.24 million.
For the full year, analysts anticipate top line of $ 25448.20 million, while looking forward to income of $ 15.64 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 25,000.00 million ~ $ 25,600.00 million, where as bottomline are predicted in a range of $ 14.85 ~ $ 15.60 per share
Click Here For More Historical Outlooks Of Amgen Inc.
Previous Quarter Performance
Amgen Inc. reported income for the first quarter of $ 4.17 per share, from the revenue of $ 6,161.00 million. The quarterly earnings decreased 5.41 percent while revenues compared with the same quarter last year.
Street analysts expected Amgen Inc. to report income of $ 3.76 per share on revenue of $ 5,980.00 million for the first quarter. The bottom line results beat street analysts by $ 0.41 or 10.90 percent, at the same time, top line results outshined analysts by $ 181.00 million or 3.03 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Amgen Inc.
Stock Performance
According to the previous trading day, closing price of AMGN was $ 253.65, representing a 45.55 % increase from the 52 week low of $ 174.27 and a 4.27 % decrease over the 52 week high of $ 264.97.
The company has a market capital of $ 149.21 billion and is part of the Healthcare sector and Drug Manufacturers – Major industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”AMGN” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
- On 15th July 2020, maintained by Morgan Stanley at Overweight rating, with $ 285.00 target price.
- On 18th June 2020, maintained by JPMorgan Chase & Co. at Neutral rating, with $ 225.00 target price.
Conference Call
Amgen Inc. will be hosting a conference call at 5:00 PM eastern time on 28th July 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.amgen.com
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience.
